StreetInsider.com News Articles

Raymond James on Dianthus Therapeutics (DNTH) Amid 8% Gain: 'Incrementally More Bullish On The CIDP Program (again)'

Fri, 12 Jun 2026 14:53:19 -0400

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

The analyst comments "DNTH reported additional data from Part A of their Phase 3 CAPTIVATE study evaluating claseprubart in CIDP showing a 75% responder rate in the first n=40 patients (up to 13 weeks), which is notably higher than the overall rate in the riliprubart (SNY) Phase 2 at Week 24 (~55%). Mean INCAT score change in responders was -1.6 at last evaluable visit (Week 13 or earlier), and substantial improvements were seen broadly across grip strength, MRC-SS, and I-RODS (notably patient-reported)

Raymond James on Dianthus Therapeutics (DNTH) Amid 8% Gain: 'Incrementally More Bullish On The CIDP Program (again)'

Fri, 12 Jun 2026 14:53:19 -0400

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

Form 8-K Dianthus Therapeutics, For: Jun 12

Fri, 12 Jun 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260612/26638162.html

Form 8-K Dianthus Therapeutics, For: Jun 12

Fri, 12 Jun 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260612/26638162.html

Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'

Wed, 10 Jun 2026 16:10:32 -0400

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $200.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)

The analyst comments "Sanofi (SNY)'s decision to stop the Phase 3 MOBILIZE study of riliprubart in SOC-refractory CIDP at the pre-specified interim has driven fair investor scrutiny to DNTH's CAPTIVATE program, but on balance we see today's news as constructive for claseprubart. Mgmt views it as a net positive, and we agree, for four reasons: (1) potency — claseprubart is ~7× more potent than riliprubart at IC90, but Sanofi was only dosing ~4× higher, implying riliprubart likely failed to achieve the target coverage required

Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'

Wed, 10 Jun 2026 16:10:32 -0400

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $200.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)

Dianthus Therapeutics (DNTH) PT Raised to $132 at Jefferies

Wed, 10 Jun 2026 15:52:12 -0400

Jefferies analyst Maury Raycroft raised the price target on Dianthus Therapeutics (NASDAQ: DNTH) to $132.00 (from $110.00) while maintaining a Buy rating.

Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'

Wed, 10 Jun 2026 13:37:50 -0400

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

The analyst comments "Sanofi announced it is stopping its Phase 3 study evaluating riliprubart in refractory CIDP patients, a C1s inhibitor and direct competitor to claseprubart, due to an interim readout analysis suggesting lack of efficacy (but not safety). Recall, Sanofi is running two phase 3 studies to support a potential BLA submission in CIDP, with the other Phase 3 comparing riliprubart vs. IVIG (readout pending). In contrast, Dianthus is running a single placebo-controlled study to support a potential sBLA for claseprubart

Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'

Wed, 10 Jun 2026 13:37:50 -0400

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'

Wed, 10 Jun 2026 13:37:50 -0400

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'

Wed, 10 Jun 2026 13:37:50 -0400

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

TD Cowen Defending Dianthus Therapeutics (DNTH): 'We see weakness as a buying opportunity'

Wed, 10 Jun 2026 13:37:06 -0400

TD Cowen analyst Yaron Werber reiterated a Buy rating on Dianthus Therapeutics (NASDAQ: DNTH).

The analyst comments "SNY stopping riliprubart's MOBILIZE on futility is molecule/trial-specific rather than thesisbreaking for DNTH. DNTH mgmt notes Ph3 CAPTIVATE for claseprubart (C1s) continues to show high response rates across all 3 pt segments, including IVIg-refractory, with a more stringent responder rate definition, stronger potency, and potentially smaller/faster Ph3. We see weakness as a buying opportunity."

For an analyst ratings summary and ratings history on Dianthus Therapeutics click here. For more ratings news on Dianthus Therapeutics click here.

Shares of Dianthus Therapeutics closed at $84.57 yesterday.

TD Cowen Defending Dianthus Therapeutics (DNTH): 'We see weakness as a buying opportunity'

Wed, 10 Jun 2026 13:37:06 -0400

TD Cowen analyst Yaron Werber reiterated a Buy rating on Dianthus Therapeutics (NASDAQ: DNTH).

For an analyst ratings summary and ratings history on Dianthus Therapeutics click here. For more ratings news on Dianthus Therapeutics click here.

Shares of Dianthus Therapeutics closed at $84.57 yesterday.

Wolfe Research on Dianthus Therapeutics (DNTH): 'Not a negative but also not a strong positive'

Wed, 10 Jun 2026 10:40:17 -0400

Wolfe Research analyst Andy Chen reiterated an Outperform rating and $98.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)

The analyst comments "This morning, Sanofi stopped the MOBILIZE Ph3 study of riliprubart in CIDP (NCT06290128, in SOC-refractory patients) due to underwhelming efficacy at an interim analysis, with no new safety signals. DNTH stock traded to $65/sh from $85/ sh as a readthrough (−23%). This appears to be a strong overreaction and we expect an eventual rebound. A few points of consideration: For long-term investors: ● Buyside had been previously hesitant whether potency & dosing would make a difference between Dianthus & Sanofi

Wolfe Research on Dianthus Therapeutics (DNTH): 'Not a negative but also not a strong positive'

Wed, 10 Jun 2026 10:40:17 -0400

Wolfe Research analyst Andy Chen reiterated an Outperform rating and $98.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)

Truist on Dianthus Therapeutics (DNTH) Amid Extreme Selloff: 'we believe the readthrough to DNTH should be limited'

Wed, 10 Jun 2026 10:38:13 -0400

Truist Securities analyst Danielle Brill reiterated a Buy rating and $110.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

The analyst comments "This morning, DNTH’s direct competitor Sanofi (SNY, NR) announced the discontinuation of one of its two pivotal CIDP trials evaluating riliprubart, its active C1s inhibitor. The discontinued study, MOBILIZE, was a placebo-controlled trial in treatment-refractory CIDP and was halted following an interim futility analysis (with no reported safety concerns). Sanofi’s second trial, VITALIZE, a head-to-head study versus IVIg in treatment-responsive CIDP, remains ongoing, though its future is now under review in light of the MOBILIZE outcome. While the futility-driven discontinuation

Truist on Dianthus Therapeutics (DNTH) Amid Extreme Selloff: 'we believe the readthrough to DNTH should be limited'

Wed, 10 Jun 2026 10:38:13 -0400

Truist Securities analyst Danielle Brill reiterated a Buy rating and $110.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

Dianthus Therapeutics (DNTH) Reiterated at Buy by Stifel

Wed, 10 Jun 2026 07:21:24 -0400

Stifel analyst Alex Thompson reiterated a Buy rating and $120.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

The analyst commented, "Sanofi announced this morning that they are discontinuing the MOBILIZE Ph3 of Riliprubart in CIDP patients refractory to IVIg. This was based on an IDMC interim which found that it’s unlikely to yield sufficient efficacy. Importantly, no safety signals were identified and the VITALIZE Ph3 study in IVIg-experienced patients remains ongoing for now. For DNTH, we remain confident in the breadth of the C1s MoA in CIDP and MG with potential more broadly (i.e., MMN+)—Notably, activity was robust in the VITALIZE

Form 4 Dianthus Therapeutics, For: Jun 01 Filed by: Randhawa Simrat

Tue, 02 Jun 2026 19:00:00 -0400

si-local-file:///var/storage/secattach/20260602/26593802.html

Form 4 Dianthus Therapeutics, For: Jun 01 Filed by: Randhawa Simrat

Tue, 02 Jun 2026 19:00:00 -0400

si-local-file:///var/storage/secattach/20260602/26593802.html

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on June 1, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 60,000 shares of the Company's

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 60,000 shares of the Company's

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 60,000 shares of the Company's

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:01:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 60,000 shares of the Company's

Form 144 Dianthus Therapeutics, Filed by: Randhawa Simrat

Mon, 01 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260601/26583761.html